Neurones
French IT services and consulting firm running service desks, SAP support, and infrastructure projects for large accounts.
Neurones is outgrowing a shrinking French market today, but its core billable-hours work is exactly what AI support tools are built to automate, and Capgemini can outspend it on that shift.
Neurones provides IT support and maintenance work, mostly for large companies in France. It is hard to replace because it has long-standing client relationships and runs a tight operation, but so do bigger competitors like Capgemini and Accenture, which means Neurones competes mostly on execution and discipline rather than something truly unique. The real threat is that AI tools are starting to automate the exact work Neurones sells, such as help desk support and routine system fixes, which could shrink the hours it bills before new projects come along to replace that lost work.
Neurones' organic growth rate converges to the French IT services sector average. would show its execution edge over rivals like Capgemini and Sopra Steria is fading.
Loss or non-renewal of a flagship public-sector or banking support contract, reported in French business press. would show a large incumbent or AI-native competitor is displacing Neurones on its home turf.
- FY2025 revenue 857.2 million euros, +5.1% organic
- Q1 2026 operating margin 9%, up from 8.2%
- Net cash 336.6 million euros, about 14 euros per share
- Billable-hours core (service desk, L1/L2 support, SAP maintenance) directly exposed to AI copilot automation.
- No proprietary AI IP or platform disclosed; advantage is relationships/execution not structural moat.
- Founder Luc de Chammard has led company since 1984 with no disclosed succession plan.
- FY2026 guidance explicitly caveated by economic uncertainties tied to international situation.
- Stock underperformed CAC 40 by roughly 27% over one year despite stable fundamentals.
| Rival | Direction | Evidence |
|---|---|---|
| Capgemini | contesting | 10x+ larger market cap (~€17-24bn vs Neurones ~€835-855M), no structural exclusion, as of Jul 2026 |
| Sopra Steria | contesting | Similar French IT services model competing for same enterprise accounts, mid-2026 |
| Accenture | contesting | Global integrator overlapping Neurones's consulting and infrastructure lines |
| AWS/Azure/Google Cloud (hyperscalers) | gaining on | Increasingly capturing cloud-integration revenue historically held by firms like Neurones |
- Is Neurones profitable in 2026?
- Yes. Neurones posted FY2025 net profit of €52.1M (stable vs €52.5M in 2024) as of March 11, 2026, and Q1 2026 operating margin rose to 9% from 8.2% a year earlier, with revenue of €227.7M reported May 6, 2026.
- Could AI replace Neurones's core business?
- Much of Neurones's Infrastructure and Applications work, service desk, L1/L2 support, SAP maintenance, is standardized billable-hours labor that AI copilots and agentic tools can automate. The company has no disclosed proprietary AI IP, only positions itself as an AI services integrator as of March 11, 2026.
- Who is Neurones's biggest competitor?
- Capgemini is the dominant adjacent incumbent, over 10 times larger by market cap (roughly €17-24bn vs Neurones's ~€835-855M as of July 9, 2026). Sopra Steria and Accenture compete in the same accounts with an identical services model.
- Who owns Neurones?
- Neurones is publicly listed on Euronext Paris (ticker NRO) and remains founder-led. Luc de Chammard has been Chairman and CEO since December 5, 1984, with family involvement continuing via board member Daphné de Chammard, per a July 9, 2026 profile.
- Is Neurones growing faster than the French IT services market?
- Yes. Neurones grew organic revenue 5.1% in FY2025 to €857.2M while the French Consulting & Digital Services market contracted 1.8%, per Euronext disclosure dated February 11, 2026. Q1 2026 organic growth accelerated further to 5.6%.
- Will Neurones be acquired by a larger rival like Capgemini?
- No acquisition, LBO, or takeover activity has been reported. Neurones remains an independent, founder-led, organically listed mid-cap with market cap near €835-855M as of July 9, 2026, though its lack of structural moat leaves it theoretically exposed to larger competitors.
- 2026-06-22Treasury shares reported at 486,000 (~2% of capital) held as of June 19, 2026
- 2026-06-04Shareholders meeting approves dividend of €1.4/share, up 7.7%
- 2026-05-14FY2026 guidance set at ~€900M revenue and ~9% operating margin
- 2026-05-06Q1 2026 revenue €227.7M, +5.6% organic growth, margin at 9%
- 2026-03-12Share buyback program begins, runs through April 20, 2026
- 2026-03-11FY2025 net profit €52.1M stable; net cash reaches €336.6M
- 2026-02-11FY2025 revenue €857.2M, +5.1% organic vs sector -1.8%
- 2021-02-10Headcount reported at roughly 5,600 experts
- 5.1% organic growth in 2025 (2026-02-11)
- + 5.6% organic growth in Q1 2026 (2026-05-06)
- Net profit, Group share stable in 2025 (2026-03-11)
- Assessing Neurones (ENXTPA:NRO) Valuation After 2026 Guidance (2026-05-14)
- Neurones SA, NRO:PAR profile (2026-07-09)
- n.d. (2026-06-22)
- Net profit, Group share stable in 2025 (2026-03-11)
- n.d. (2021-02-10)
- Neurones (NRO) Investor Relations, Earnings Summary & Outlook (2026-06-30)
- Neurones Company Profile & Executives - WSJ
- Prezzo dei titoli... Neurones S.A. (2026-02-25)
- Alten (ENXTPA:ATE) (2026-07-05)